AddLife: Healthcare 21 Acquisition
Former General Manager at Aquilant, HC 21 (now owned by AddLife)
inpractise.com/articles/addlife-healthcare-21
Former General Manager at Aquilant, HC 21 (now owned by AddLife)
Lifelong Healthcare sales executives at both the manufacturer and distributor level with 35 years of experience in the industry and formerly in charge of the consumables business at Aquilant from 2012 to 2019. The executive was part of the negotiation to sell the business to the PE buyer who then immediately merged Aquilant with HC21, now owned by AddLife.
Interview Transcript
This is a snippet of the transcript, sign up to read more.
How dependent is Aquilant on any one of these larger suppliers?
Some exited and we were never wholly dependent but some of them hurt. The way we structured the company was each product area had its own team, which is partly because of the intensive nature of working with them in hospitals. You need product area experts and a large number of people. From a purely commercial bottom line, if somebody major exited we could restructure a small part of the business and the overall impact on the group bottom line wasn't massive. It would be redundancies or restructuring, which protects because we ran each therapy area as its own business, so we were able to do that without massive disruption to the rest of the organization.
This is a snippet of the transcript, sign up to read more.
Was the idea that Aquilant would lead the new company rather than HC 21?
Healthcare 21 was never in the picture until the day it was done; it was always going to be Aquilant looking for acquisitions. They saw the opportunity to do a deal with one of our acquisition targets and roll the two together in a way that worked for them financially because it minimized their outlay. Whatever they paid for Aquilant, they probably paid for Healthcare 21, but I don't know whether it was an easy option to get a 50% stake in a bigger organization which gives an instant return on investment.
This is a snippet of the transcript, sign up to read more.
Related Content
Copyright Notice
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2024 IP 1 Ltd. All rights reserved.